STOCKHOLDERS’ EQUITY

9 Months Ended

Sep. 30, 2025

Equity [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 8 – STOCKHOLDERS’ EQUITY

Stock Compensation

The Company offers incentive stock option grants to directors and key employees. Options vest in tranches and typically expire five (5) years from the date of grant. For the nine (9) months ended September 30, 2025, and 2024, the Company recorded stock option expense of ($21,678) and $747,686, respectively. For the three (3) months ended September 30, 2025, and 2024, the Company recorded stock option expense of ($505,691) and $300,940, respectively. The option expense not taken as of September 30, 2025, is $2,097,462, with a weighted average term of 2.27 years.

The following table represents stock option activity as of and for the nine (9) months ended September 30, 2025:

	Number of		Weighted Average		Weighted Average		Aggregate
	Shares		Exercise Price		Remaining Life		Intrinsic Value
Options Outstanding – December 31, 2024	5,650,000		$	0.78		3.80	$	—
Granted	—			—
Exercised	(500,000	)		0.14		4.08		—
Forfeited	(1,575,000	)		—				—
Options Outstanding – September 30, 2025	3,575,000		$	0.44		1.45	$	—
Exercisable and Vested, September 30, 2025	1,876,664		$	0.64		1.64	$	—

The aggregate intrinsic value for options outstanding as of September 30, 2025, is not calculated because the closing stock price on September 30, 2025, is less than the weighted average exercise price of outstanding options on that date.